Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Breast Cancer Research

Fig. 3

From: Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis

Fig. 3

MDA-MB-231-LN cell tumor growth was inhibited by the combination of maraviroc and tocilizumab. a Generation of MDA-MB-231-LN cell xenografts administered maraviroc, tocilizumab, and the combination of maraviroc and tocilizumab. b Tumor growth curves of MDA-MB-231-LN cells implanted mammary fat pad in athymic mice treated with maraviroc (8 mg/kg body weight, R&D systems) orally daily; cMR16-1 (10 mg/kg, Genentech) intraperitoneally 3 days per week for 5 weeks (mean ± SEM, **P < 0.005, n = 10). c Size of MDA-MB-231-LN cells xenografts in athymic nude mice after 5 weeks of treatment with maraviroc and cMR16-1. TCM, tumor-conditioned medium

Back to article page